<?xml version="1.0" encoding="UTF-8"?>
<ref id="bph15092-bib-0101">
 <mixed-citation publication-type="journal" id="bph15092-cit-0102">
  <string-name>
   <surname>Xia</surname>, 
   <given-names>S.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liu</surname>, 
   <given-names>M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>, 
   <given-names>C.</given-names>
  </string-name>, 
  <string-name>
   <surname>Xu</surname>, 
   <given-names>W.</given-names>
  </string-name>, 
  <string-name>
   <surname>Lan</surname>, 
   <given-names>Q.</given-names>
  </string-name>, 
  <string-name>
   <surname>Feng</surname>, 
   <given-names>S.</given-names>
  </string-name>, … 
  <string-name>
   <surname>Lu</surname>, 
   <given-names>Lu</given-names>
  </string-name> (
  <year>2020</year>). 
  <article-title>Inhibition of SARS‐CoV‐2 (previously 2019‐nCoV) infection by a highly potent pan‐coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title>. 
  <source xml:lang="en">Cell Research</source>, 
  <volume>30</volume>(
  <issue>4</issue>), 
  <fpage>343</fpage>–
  <lpage>355</lpage>. 
  <pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>
  <pub-id pub-id-type="pmid">32231345</pub-id>
 </mixed-citation>
</ref>
